featured
Crizotinib for MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
Clin. Cancer Res 2019 Nov 08;[EPub Ahead of Print], L Landi, R Chiari, M Tiseo, et alFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.